US Food and Drug Administration. Arzerra (ofatumumab) and Rituxan (rituximab): drug safety communication - new boxed warning, recommendations to decrease risk of hepatitis B reactivation. September 25, 2013. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm366406.htm. Accessed March 26, 2018.